Article Text

other Versions

PDF
Long-term efficacy and safety of firocoxib in the treatment of dogs with osteoarthritis
  1. A. Autefage, DVM, PhD, DECVS1,
  2. F. M. Palissier, DVM1,
  3. E. Asimus, DVM, PhD1 and
  4. C. Pepin-Richard, DVM2
  1. Unité de Chirurgie, Département des Sciences Cliniques des Animaux de Compagnie, Ecole Nationale Vétérinaire de Toulouse, 23 Chemin des Capelles, BP 87614, 31076 Toulouse Cedex 3, France
  2. Merial, 13b Avenue Albert Einstein, 69100 Villeurbanne, France
  1. E-mail for correspondence a.autefage{at}envt.fr

Thirty-nine client-owned dogs with osteoarthritis were treated with 5 mg/kg firocoxib administered orally, once a day for 52 weeks. Veterinary examinations were performed on approximately days 0, 15, 90, 180, 270 and 360. Twenty-five dogs completed the study. The withdrawal rate associated with gastrointestinal side effects was low (5.1 per cent of dogs). Based on the owners' assessment, 82 per cent of the dogs had improved at day 15, 84 per cent of the 32 remaining dogs had improved at day 90, and 96 per cent of the 25 dogs that completed the trial had improved at day 360. During this trial, 12 (48 per cent) of the 25 remaining dogs showed an improvement in their lameness from day 90 to day 360 (P<0.05).

Statistics from Altmetric.com

Footnotes

  • Provenance not commissioned; externally peer reviewed

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.